Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| XCOPRI | 12.5MG; 25MG; 50MG; 100MG; 150MG; 200MG | tablet · oral | SK LIFE | Prescription | 21 Nov 2019 |
Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| XCOPRI | 02538652 | 12.5 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538660 | 25 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538725 | 50 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538733 | 100 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538741 | 150 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538768 | 200 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538776 | 25 MG; 12.5 MG | KIT; TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| XCOPRI | 02538784 | 100 MG; 50 MG | KIT; TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | XCOPRI 100 MG TABLET | $39.87152 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 12.5-25 MG TITRATION PK | $3.91043 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 150 MG TABLET | $39.8629 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 150-200 MG TITRATION PK | $42.9098 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 200 MG TABLET | $39.8775 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 25 MG TABLET | $39.88192 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 250 MG DAILY DOSE PACK | $21.36879 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 350 MG DAILY DOSE PACK | $42.69935 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 50 MG TABLET | $39.85674 | per EA | 23 Sep 2026 |
| US NADAC | XCOPRI 50-100 MG TITRATION PAK | $42.71457 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cenobamate 100mg tablets | £87.36 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 100mg tablets | £136.50 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 12.5mg tablets and Cenobamate 25mg tablets | £165.62 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 150mg tablets | £89.18 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 150mg tablets | £182.00 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 200mg tablets | £91.00 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 200mg tablets | £182.00 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 50mg tablets | £85.54 | 14 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cenobamate 50mg tablets | £91.00 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.